GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab

A Retrospective Longitudinal Database Study of Persistence and Compliance with Treatment of Osteoporosis in Hungary

(2015) Péter Lakatos et al.   CALCIFIED TISSUE INTERNATIONAL

Treatment Satisfaction in Postmenopausal Women Suboptimally Adherent to Bisphosphonates Who Transitioned to Denosumab Compared With Risedronate or Ibandronate

(2015) Santiago Palacios et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study

(2015) P. Hadji et al.   OSTEOPOROSIS INTERNATIONAL

Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis

(2015) L. Karlsson et al.   OSTEOPOROSIS INTERNATIONAL

Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study

(2014) S. L. Silverman et al.   OSTEOPOROSIS INTERNATIONAL

Osteoporosis Treatment: When to Discontinue and When to Re-start

(2014) Silvano Adami et al.   Bone Research

Reduction in the Risk of Clinical Fractures After a Single Dose of Zoledronic Acid 5 Milligrams

(2013) I. R. Reid et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Medication adherence and fracture risk among patients on bisphosphonate therapy in a large United States health plan

(2012) Sally W. Wade et al.   BONE

Persistence and compliance of medications used in the treatment of osteoporosis – analysis using a large scale, representative, longitudinal German database

(2012) Volker Ziller et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Adverse Effects of Bisphosphonates: Implications for Osteoporosis Management

(2012) Kurt A. Kennel et al.   MAYO CLINIC PROCEEDINGS

Persistence with intravenous zoledronate in elderly patients with osteoporosis

(2011) Y.-K. Lee et al.   OSTEOPOROSIS INTERNATIONAL

Treatment satisfaction and persistence among postmenopausal women on osteoporosis medications: 12-month results from POSSIBLE US™

(2011) E. Barrett-Connor et al.   OSTEOPOROSIS INTERNATIONAL

GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates

(2011) P. Hadji et al.   OSTEOPOROSIS INTERNATIONAL

Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women

(2011) N. Freemantle et al.   OSTEOPOROSIS INTERNATIONAL

A Meta-Analysis of Osteoporotic Fracture Risk with Medication Nonadherence

(2011) Susan Ross et al.   VALUE IN HEALTH

Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate

(2010) D. L. Kendler et al.   OSTEOPOROSIS INTERNATIONAL

Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis

(2010) B. Jönsson et al.   OSTEOPOROSIS INTERNATIONAL

Compliance and treatment satisfaction of post menopausal women treated for osteoporosis. Compliance with osteoporosis treatment

(2010) Dominique Huas et al.   BMC Womens Health

Impact of Osteoporosis Treatment Adherence on Fracture Rates in North America and Europe

(2009) Ethel S. Siris et al.   AMERICAN JOURNAL OF MEDICINE

Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: A retrospective case—control analysis

(2009) François-Emery Cotté et al.   CLINICAL THERAPEUTICS

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy

(2009) David L Kendler et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass

(2009) D. L. Kendler et al.   OSTEOPOROSIS INTERNATIONAL

Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial*

(2008) Jacques P Brown et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock-In Mice That Express Chimeric (Murine/Human) RANKL*

(2008) Paul J Kostenuik et al.   JOURNAL OF BONE AND MINERAL RESEARCH